Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pendulum Glucose Control (Pendulum Therapeutics)
- Development stage
- Unknown
- Lead developer
- Pendulum Therapeutics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Pendulum Glucose Control is a multi-strain probiotic supplement developed by Pendulum Therapeutics, containing a proprietary blend of five live bacterial strains—*Akkermansia muciniphila*, *Clostridium butyricum*, *Clostridium beijerinckii*, *Anaerobutyricum hallii*, and *Bifidobacterium infantis*—along with the prebiotic chicory inulin. Originally designed and marketed for the management of type 2 diabetes to improve glucose control and A1C levels, the formulation is currently being evaluated in a Phase 1 clinical trial at the University of Cincinnati for its potential to mitigate radiation-induced gastrointestinal (GI) toxicity in patients receiving pelvic radiotherapy. The therapeutic rationale is based on the ability of these specific strains to restore gut microbiome homeostasis and strengthen the intestinal barrier; notably, *A. muciniphila* is thought to promote mucus layer maintenance and epithelial repair, thereby reducing the severity of GI symptoms associated with radiation-induced injury.
- Brand names
- Pendulum Glucose Control
- Other names
- PGC
Beyond the preview
Go deeper on Pendulum Glucose Control (Pendulum Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pendulum Glucose Control (Pendulum Therapeutics).